Log In
BCIQ
Print this Print this
 

ALN-PDL

  Manage Alerts
Collapse Summary General Information
Company Alnylam Pharmaceuticals Inc.
DescriptionRNAi therapeutic targeting hepatocyte-expressed programmed cell death 1 ligand 1 (PD-L1) (B7-H1) (CD274) developed using Alnylam's Enhanced Stabilization Chemistry (ESC)-GalNAc-conjugate technology
Molecular Target Programmed cell death 1 ligand 1 (PD-L1) (B7-H1) (CD274)
Mechanism of Action 
Therapeutic ModalityNucleic acid: Linear RNA
Latest Stage of DevelopmentPreclinical
Standard Indication Infectious (unspecified)
Indication DetailsTreat chronic liver infections
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today